Cyclerion Therapeutics (NASDAQ:CYCN – Get Free Report) and Nutriband (NASDAQ:NTRB – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their profitability, earnings, valuation, institutional ownership, dividends, analyst recommendations and risk.
Profitability
This table compares Cyclerion Therapeutics and Nutriband’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cyclerion Therapeutics | -170.11% | -87.96% | -74.86% |
| Nutriband | -448.25% | -112.64% | -97.86% |
Analyst Recommendations
This is a breakdown of current ratings and target prices for Cyclerion Therapeutics and Nutriband, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cyclerion Therapeutics | 1 | 0 | 0 | 0 | 1.00 |
| Nutriband | 1 | 1 | 0 | 0 | 1.50 |
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cyclerion Therapeutics | $2.07 million | 11.02 | -$3.53 million | ($1.66) | -2.94 |
| Nutriband | $2.04 million | 33.58 | -$8.23 million | ($2.58) | -2.18 |
Cyclerion Therapeutics has higher revenue and earnings than Nutriband. Cyclerion Therapeutics is trading at a lower price-to-earnings ratio than Nutriband, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
75.6% of Cyclerion Therapeutics shares are held by institutional investors. Comparatively, 19.7% of Nutriband shares are held by institutional investors. 34.3% of Cyclerion Therapeutics shares are held by company insiders. Comparatively, 52.2% of Nutriband shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Risk & Volatility
Cyclerion Therapeutics has a beta of 1.75, indicating that its stock price is 75% more volatile than the S&P 500. Comparatively, Nutriband has a beta of 2.03, indicating that its stock price is 103% more volatile than the S&P 500.
Summary
Cyclerion Therapeutics beats Nutriband on 7 of the 12 factors compared between the two stocks.
About Cyclerion Therapeutics
Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
About Nutriband
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. It has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices; and Kindeva Drug Delivery, L.P. to develop AVERSAL Fentanyl based on its proprietary AVERSAL abuse deterrent transdermal technology. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
Receive News & Ratings for Cyclerion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclerion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
